Comparative Pharmacology
Head-to-head clinical analysis: FLOXURIDINE versus REDITREX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLOXURIDINE versus REDITREX.
FLOXURIDINE vs REDITREX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FLOXURIDINE is an antimetabolite that inhibits thymidylate synthetase, thereby blocking DNA synthesis. It is converted to 5-fluorouracil (5-FU) in the body, which is further metabolized to active nucleotides that incorporate into RNA and inhibit thymidylate synthase.
REDITREX is a folate analog metabolic inhibitor that inhibits dihydrofolate reductase (DHFR), thereby blocking the conversion of dihydrofolate to tetrahydrofolate, which is essential for purine and pyrimidine synthesis. This leads to inhibition of DNA synthesis and cell proliferation.
0.1 to 0.6 mg/kg/day via continuous intra-arterial infusion for 14 days, then 7-day rest; typical dose 0.3 mg/kg/day.
15 mg/m2 intramuscularly or intravenously once weekly; maximum single dose 30 mg.
None Documented
None Documented
Clinical Note
moderateFloxuridine + Digoxin
"Floxuridine may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateFloxuridine + Digitoxin
"Floxuridine may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateFloxuridine + Deslanoside
"Floxuridine may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateFloxuridine + Acetyldigitoxin
"Floxuridine may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal half-life is approximately 20 minutes; clinical context: rapid clearance necessitates continuous IV infusion for sustained antineoplastic effect.
Terminal elimination half-life is 3-10 hours in patients with normal renal function; prolonged to 20-40 hours in end-stage renal disease.
Primarily hepatic metabolism to inactive metabolites; renal excretion accounts for <10% of unchanged drug; biliary/fecal excretion is minor.
Primarily renal (80-90% as unchanged drug) via glomerular filtration and active tubular secretion; minimal biliary/fecal elimination (<10%).
Category C
Category C
Antineoplastic Antimetabolite
Antineoplastic Antimetabolite